In this context, 111In-DOTA-belatacept could serve as a research tool to study the approach of targeting CD80/CD86-rich APCs in atherosclerosis and possibly other inflammation-related diseases such as cancer, autoimmune disease, and rejection after organ transplantation. This evidence concerns the gene CD80 and atherosclerosis.